FindTrial
Sign In

RANDOMIZED, DOUBLE-BLIND STUDY, CONTROLLED BY ACTIVE COMPARATOR IN PARALLEL GROUPS TO EVALUATE THE SAFETY OF ETORICOXIB IN PATIENTS WITH OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS.

RANDOMIZED, DOUBLE-BLIND STUDY, CONTROLLED BY ACTIVE COMPARATOR IN PARALLEL GROUPS TO EVALUATE THE SAFETY OF ETORICOXIB IN PATIENTS WITH OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REPEC
Registry ID
PER-067-02
Enrollment
660
Registered
2003-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Etoricoxib 90 mg Type of group
Se administrara etoricoxib de 90 mg una vez al dia Group name:diclofenac sodium 150 mg Type of group
Sodium diclofenac 75 mg twice daily will be administered.

Sponsors

MERCK SHARP & DOHME PERU S.R.L.,
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The patient is male or female, is> 50 years of age, and a diagnosis of osteoarthritis or rheumatoid arthritis that, in the opinion of the researcher, will require chronic therapy of NSAIDs or selective COX-2 inhibitor by minus 1.5 year.

Exclusion criteria

Exclusion criteria: The patient is diagnosed as functional Class IV of the American College of Rheumatology (ACR). The patient has a concurrent medical or arthritic disease that could confuse or interfere with the evaluation of effectiveness.

Countries

Peru, United States

Contacts

Public ContactStela Lopez

MERCK SHARP & DOHME PERU S.R.L

stela_lopez@merck.com4115935

Outcome results

None listed

Source: REPEC (via WHO ICTRP)